PROCEPT BioRobotics Announces Extensive Clinical Presence at American Urological Association (AUA) 2020 Virtual Experience

Aquablation Therapy Clinical Trial and Real-World Data Highlight Sustained Durability, Safety and Preservation of Sexual Function for a Broad Range of BPH Patients

REDWOOD CITY, Calif.–(BUSINESS WIRE)–#AUA2020—PROCEPT® BioRobotics Corporation, a surgical robotics company developing intelligent solutions to transform the field of urology, today announced its extensive clinical presence on Aquablation® therapy at the American Urological Association (AUA) 2020 Virtual Experience.

Aquablation therapy will be featured in multiple AUA Live virtual education sessions and highlighted in several podium and poster presentations in the AUA Virtual Science Portal. The results will showcase reproducible outcomes of sustained durability and preservation of sexual function across prostates of any size through the latest clinical trial and real-world data.

During AUA Live on Sunday, June 28, two back-to-back sessions will focus on Aquablation therapy:

1. Aquablation Surgical Techniques: Tips and Tricks – Day 2, Theater 2 at 12:05 pm ET (CME Session) – Dr. Steven Kaplan will narrate a semi-live surgical video of Aquablation therapy.
2. Aquablation Therapy: Reimagining Conventions in BPH Surgical Treatment – Day 2, Theater 3 at 1 pm ET (non-CME industry-sponsored symposium)– A world-renowned global faculty will discuss pivotal questions in BPH surgery today and engage in live Q&A with the audience.

The latest Aquablation therapy clinical trial data are available now, and include two podium presentations and a moderated poster in the AUA Virtual Science Portal:

1. Three-Year Outcomes After Aquablation Compared to TURP: Efficacy & Ejaculatory Improvement Sustained – Efficacy and safety outcomes sustained for 36 months, with Aquablation therapy demonstrating superior symptom relief and safety outcomes compared to TURP for prostates greater than or equal to 50-80mL.
2. WATER vs. WATER II – Two-Year Comparison of Aquablation Therapy for Benign Prostatic Hyperplasia – Aquablation therapy offers standardized clinical outcomes among patients regardless of prostate size or shape.
3. Aquablation for BPH in Large Prostates (80-150mL): 2-Year Results – Durable efficacy and safety outcomes sustained out to two years in large prostates.

Additionally, data highlighting the real-world experience with Aquablation therapy are also available now and include two notable podium presentations in the AUA Virtual Science Portal:

1. Transfusion Rates After 800 Aquablation Procedures Using Various Hemostasis Methods – Optimal hemostasis technique following Aquablation therapy provides low transfusion rates in a broad range of prostates.
2. Predictors of Anejaculation After Aquablation Procedure for BPH – Real-time intraoperative TRUS imaging enables the avoidance of anatomic structures involved in ejaculation, improving preservation of ejaculatory function following Aquablation therapy.

“We continue to realize positive and reproducible outcomes through our longer term clinical trial results and real-world experiences,” said Reza Zadno, president and chief executive officer of PROCEPT BioRobotics. “Our extensive presence highlighted at the AUA 2020 Virtual Experience validates the clinical value of this procedure for prostates of all sizes. Aquablation therapy is strongly positioned to become the treatment of choice that fills the existing void for a durable, resective procedure that has a minimal risk of irreversible complications, including sexual side effects.”

For more information regarding PROCEPT’s extensive programming at this year’s AUA, visit https://www.procept-biorobotics.com/aua2020/.

About PROCEPT BioRobotics Corporation and Aquablation Therapy

PROCEPT BioRobotics is a surgical robotics company enabling better patient care by developing transformative solutions in urology. With an initial focus on BPH, the AquaBeam® Robotic System delivering Aquablation therapy, is the first FDA-cleared, automated surgical robot for the treatment of lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH). Aquablation therapy combines real-time, multi-dimensional imaging, automated robotics and heat-free waterjet ablation for targeted, controlled, and immediate removal of prostate tissue. Aquablation therapy offers predictable and reproducible outcomes, independent of prostate anatomy, prostate size or surgeon experience. For more information visit https://www.procept-biorobotics.com.

Important Safety Information

All surgical treatments have inherent and associated side effects. The most common side effects are mild and transient, and may include mild pain or difficulty when urinating, discomfort in the pelvis, blood in the urine, inability to empty the bladder or a frequent and/or urgent need to urinate, and bladder or urinary tract infection. Other risks include ejaculatory dysfunction and a low risk of injury to the urethra or rectum where the devices gain access to the body for treatment. For more information about potential side effects and risks associated with Aquablation therapy, speak with your urologist or surgeon. No claim is made that the AquaBeam Robotic System will cure any medical condition, or entirely eliminate the diseased entity. Repeated treatment or alternative therapies may sometimes be required.

Contacts

Diana Soltesz

Pazanga Health Communications Inc.

818-618-5634

[email protected]